SEC EDGARAUG 131 min read$TAK

Pacheco Rhonda Janice sold $289K of TAK

Pacheco Rhonda Janice (President, U.S. Business Unit) sold 16,901 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $17.10 ($0.29M total) on 2026-08-10.

Original reporting

SEC EDGAR · Pacheco Rhonda Janice

Published Aug 13, 2026, 1:53 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 13, 2026, 2:02 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$TAK

Neutral

medium confidence

Mentioned

$TAK

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$TAKNeutralLow

Why it matters

Traders may monitor insider activity as a sentiment input, but this disclosure does not change company fundamentals or near-term guidance.

Market read

A dated insider sale was disclosed via Form 4, offering limited incremental information beyond routine insider-trading monitoring.

What to watch

The filing does not disclose reasons for the sale, and the post-transaction holdings remain substantial (182,507 shares), limiting interpretability.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12, sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for Takeda Pharmaceutical Co Ltd.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TAKNeutralMedium confidence

Context

Takeda’s Form 4 shows officer Rhonda Janice Pacheco sold 16,901 shares at $17.10 on 2026-08-10 for about $289K.

Expected impact

Likely minimal near-term impact; any effect would be limited to short-term sentiment around insider selling.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction size is modest versus a large-cap and provides no new operational or guidance information.

Market effects

Sector

No clear sector read-through from a single, modest insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be planned for diversification or taxes; absence of a stated 10b5-1 plan does not necessarily imply negative expectations.

Key entities

issuer
TAK
Takeda Pharmaceutical Co Ltd, the company whose insider transaction was reported.
insider
Rhonda Janice Pacheco
President, U.S. Business Unit, who reported an open-market sale.

Read at source ← All news

OCT 6

$TAKMedAI 9/10

Why Zasocitinib Outperformed Deucravacitinib in New Plaque Psoriasis Data

Zasocitinib, an investigational TYK2 inhibitor by Takeda, showed superior efficacy in treating plaque psoriasis compared to deucravacitinib in a phase 3 trial. 36.5% of patients achieved PASI 100 with zasocitinib vs. 13.9% with deucravacitinib. The drug's higher TYK2 selectivity and longer IL-23 blockade were cited as key factors. Zasocitinib is under review by the FDA and EMA.

hcplive.com2 min

OCT 3

$PFEHighAI 9/10

Targeted Drug Duo with Lighter Chemotherapy Delivers 97% Survival in

A phase 2 trial showed a regimen combining brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine achieved 92% complete response and 97% 2-year progression-free survival in early-stage Hodgkin lymphoma. The study, published in Advances in Therapy, involved 154 patients and was funded by Seagen (now Pfizer), Takeda, and Bristol-Myers Squibb.

bioengineer.org3 min

OCT 2

$BIIBMed

CMS's GLOBE Drug Pricing Plan Collapses to $400M in Savings, Leaving a Four-Company Test

CMS's GLOBE drug pricing plan's projected savings dropped from $11.9B to $400M, affecting about four manufacturers, including Biogen, Takeda, and Daiichi Sankyo. The reduction is due to exclusions for GARD participants. The final rule may face legal challenges and has raised concerns about its effectiveness.

finance.biggo.com4 min

SEP 30

$TAKHighAI 9/10

Oveporexton Improves Wakefulness and Cataplexy in Narcolepsy Type 1

Takeda's Oveporexton (Orzeyful) significantly improved wakefulness, daytime sleepiness, and cataplexy in narcolepsy type 1 patients over 12 weeks, according to two phase 3 trials. The FDA approved the drug in August 2026, positioning it as the first therapy addressing orexin deficiency. Adverse events included increased urinary frequency and transient insomnia. Trials showed mean sleep latency improvements of 14.3 to 19.8 minutes with Oveporexton vs. placebo.

ajmc.com3 min

SEP 30

$TAKMedAI 8/10

Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

Takeda announced Phase 3 trial results showing zasocitinib (TAK-279) demonstrated superior efficacy in treating moderate-to-severe plaque psoriasis compared to deucravacitinib. Key data: 36.5% of patients achieved complete skin clearance (PASI 100) at week 16 vs. 13.9% for deucravacitinib. Zasocitinib also showed durable skin clearance and improvements in itch and quality of life. The drug is under regulatory review for psoriasis treatment.

intelligencer.ca2 min

SEP 22